Table 1.
Baseline Characteristics for the Entire Cohort and for Each Study Group
| Characteristics | Overall (N = 952) | CMV Controllers (n = 282) | CMV Non-controllers (n = 93) | Elite-controllers (n = 275) | R−D− (n = 302) | P Value |
|---|---|---|---|---|---|---|
| Demographic characteristics | ||||||
| Age, y, median (IQR) | 57 (47–65) | 58 (48–66) | 58 (48–66) | 56 (45–64) | 57 (47–65) | .191 |
| Sex | .006 | |||||
| Female | 388 (40.8) | 118 (41.8) | 48 (51.6) | 121 (44.0) | 101 (33.4) | |
| Male | 564 (59.2) | 164 (58.2) | 45 (48.4) | 154 (56.0) | 201 (66.6) | |
| Transplant characteristics | ||||||
| CMV R serostatus | <.001 | |||||
| R− | 443 (46.5) | 13 (4.6) | 2 (2.2) | 126 (45.8) | 302 (100.0) | |
| R+ | 509 (53.5) | 269 (95.4) | 91 (97.8) | 149 (54.2) | 0 (0.0) | |
| CMV D serostatus | <.001 | |||||
| D− | 511 (53.7) | 92 (32.6) | 45 (48.4) | 72 (26.2) | 302 (100.0) | |
| D+ | 441 (46.3) | 190 (67.4) | 48 (51.6) | 203 (73.8) | 0 (0.0) | |
| Underlying disease | .003 | |||||
| Leukemia | 523 (54.9) | 161 (57.1) | 61 (65.6) | 157 (57.1) | 144 (47.7) | |
| Lymphoma | 197 (20.7) | 52 (18.4) | 7 (7.5) | 64 (23.3) | 74 (24.5) | |
| MDS | 172 (18.1) | 45 (16.0) | 19 (20.4) | 43 (15.6) | 65 (21.5) | |
| Othera | 60 (6.3) | 24 (8.5) | 6 (6.5) | 11 (4.0) | 19 (6.3) | |
| Stem cell source | .219 | |||||
| Bone marrow | 106 (11.1) | 39 (13.8) | 7 (7.5) | 32 (11.6) | 28 (9.3) | |
| Peripheral blood | 846 (88.9) | 243 (86.2) | 86 (92.5) | 243 (88.4) | 274 (90.7) | |
| Donor HLA matching | .393 | |||||
| Matched related | 318 (33.4) | 88 (31.2) | 32 (34.4) | 95 (34.5) | 103 (34.1) | |
| Matched unrelated | 476 (50.0) | 151 (53.5) | 39 (41.9) | 139 (50.5) | 147 (48.7) | |
| Mismatchedb | 158 (16.6) | 43 (15.2) | 22 (23.7) | 41 (14.9) | 52 (17.2) | |
| Graft manipulation | <.001 | |||||
| Unmodified | 557 (58.5) | 173 (61.3) | 29 (31.2) | 181 (65.8) | 174 (57.6) | |
| CD34+ selection | 395 (41.5) | 109 (38.7) | 64 (68.8) | 94 (34.2) | 128 (42.4) | |
| Conditioning intensity | .002 | |||||
| Myeloablative | 582 (61.1) | 169 (59.9) | 75 (80.6) | 151 (54.9) | 187 (61.9) | |
| Reduced | 264 (27.7) | 80 (28.4) | 16 (17.2) | 89 (32.4) | 79 (26.2) | |
| Nonmyeloablative | 106 (11.1) | 33 (11.7) | 2 (2.2) | 35 (12.7) | 36 (11.9) | |
| Acute ≥ grade 2 GVHD | .949 | |||||
| No | 552 (58.0) | 166 (58.9) | 53 (57.0) | 156 (56.7) | 177 (58.6) | |
| Yes | 400 (42.0) | 116 (41.1) | 40 (43.0) | 119 (43.3) | 125 (41.4) |
Data are No. (%) except where indicated. CMV control among patients with CMV viremia by day 100 was defined by AAUC quartiles. CMV controllers comprised patients with AAUC in the lower 3 quartiles. CMV non-controllers comprised patients with AAUC in the fourth quartile. Elite controllers comprised of R+, or R−/D+ without CMV viremia by day 100 post-HCT. P values were calculated using χ 2 tests.
Abbreviations: AAUC, averaged area under the curve of CMV viral load; CMV, cytomegalovirus; D, donor CMV serostatus; GVHD, graft versus host disease; HCT, hematopoietic cell transplant; HLA, human leucocyte antigens; IQR, interquartile range; MDS, myelodysplastic syndrome; R, recipient CMV serostatus.
aOther included myeloproliferative disorders in 41 patients, aplastic anemia in 16 patients, and nonmalignant hematologic disorders in 3 patients.
bMismatched included unrelated nonidentical donors in 110 patients, related nonidentical donors in 5 patients, and related haploidentical donors in 43 patients.